Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME trial

▴ Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME trial
In new results published in The Lancet Diabetes & Endocrinology, empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established cardiovascular disease

Empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and established cardiovascular disease over the three years of the EMPA-REG OUTCOME®trial, according to results of a new post-hoc analysis. Total cardiovascular events included 3P-MACE (a composite of non-fatal heart attack, non-fatal stroke and cardiovascular death), hospitalization for heart failure and all-cause hospitalization. The findings, announced by Boehringer Ingelheim and Eli Lilly and Company, were published in TheLancet Diabetes & Endocrinology.

“People with type 2 diabetes and established atherosclerotic cardiovascular disease are at an increased risk of cardiovascular complications often requiring recurrent admissions to hospital, imposing a significant burden on quality of life for patients and on healthcare systems,” said Darren McGuire, M.D., M.H.Sc., lead author of the analysis and Professor of Medicine at the University of Texas Southwestern Medical Center and Parkland Health and Hospital System. “Considering the totality of hospitalization events, as opposed to just the first event that is most commonly analyzed in clinical trials, better reflects the net effect of beneficial therapies. These new findings help us understand the impact of long-term treatment with empagliflozin for adults who may experience recurrent events due to these debilitating conditions.” 

Previously,the landmark EMPA-REG OUTCOME® trial showed that, in adults with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the relative risk of 3P-MACE by 14 percent, driven by a 38 percent reduction in the relative risk of cardiovascular death.

These new exploratory analyses show that, when added to standard of care, empagliflozin reduced the relative risk of the following total (first plus recurrent) events versus placebo:

  • 3P-MACE by 22 percent
  • Hospitalizations for heart failure by 42 percent
  • All-cause hospitalizations by 17 percent
  • Fatal or non-fatal myocardial infarction, commonly known as heart attack, by 21 percent
  • Coronary heart disease events (a composite of myocardial infarction and coronary revascularization) by 20 percent.

“These new findings add to previous evidence of the ability of empagliflozin to reduce cardiovascular and all-cause mortality, and in fact suggest additional positive effects of empagliflozin on hospitalization and atherosclerosis-related outcomes in people with type 2 diabetes with established cardiovascular disease,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim.

“Boehringer Ingelheim and Lilly will continue to explore how empagliflozin can potentially improve health outcomes and fill treatment gaps for adults with type 2 diabetes and heart disease,” said Jeff Emmick, M.D., Ph.D., Vice President, Product Development, Lilly. “We look forward to presenting further results from our EMPOWER program, which is one of the largest cardiovascular clinical programs for an SGLT2 inhibitor to date with more than 377,000 adults studied worldwide.”

 

About EMPA-REG OUTCOME® (NCT01131676)3

 EMPA-REG OUTCOME® was a long-term, multicenter, randomized, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including medication for the treatment of hypertension and hypercholesteremia). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

 

About the EMPOWER program

The Alliance has developed the EMPOWER program to explore the impact of empagliflozin on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually.4 Through the EMPOWER program, Boehringer Ingelheim and Lilly are working to advance knowledge of these interconnected systems and create care which offers integrated, multi-organ benefits. Comprised of nine clinical trials and two real-world evidence studies, EMPOWER reinforces the long-term commitment of the Alliance to improve outcomes for people living with cardio-renal-metabolic conditions. With more than 377,000 adults estimated to have enrolled worldwide upon completion of the studies, it is one of the broadest and most comprehensive clinical programs for an SGLT2 inhibitor to date.

Tags : #empowerprogram #type2diabetes #lilly #cardiovasculardisease #renaldisease #empagliflozin

Related Stories

23 Jan

When a Government Hospital Became a Lifesaver: The Story of India’s First ‘Mechanical Heart’ Implant

The Army Hospital’s achievement is a shining example of how determination and skill can overcome even the most daunting challenges.

View
20 Dec

Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in India

With the insights and innovations it is expected to generate, this biobank could well be the key to turning the tide against India’s diabetes epidemic.

View
07 Dec

Is Your Favorite Snack a Secret Weapon Against Diabetes?

While the Harvard study has opened new doors, Future research could also dive into the optimal dosage of flavanols and the long-term effects of regular dark chocolate intake.

View
08 Jun

Latest Research Highlights The Role of Liver Glucose Production in Type 2 Diabetes

Continued research and advancements in understanding diabetes mechanisms will lead the way for more effective treatments and better health outcomes for millions worldwide.

View
23 Mar

Bariatric Surgery Offers Hope for End-Stage Renal Disease Patients: A Breakthrough Study

The study highlights the potential of metabolic and bariatric surgery to not only facilitate weight loss but also to enhance overall health and transplant eligibility.

View
13 Mar

Genetic Insights into Hypertension: Charting the Course for Cardiovascular Wellness

As we navigate the complexities of cardiovascular health, a comprehensive understanding of genetic predispositions and environmental influences is paramount. Through concerted efforts in research, education, and clinical practice, we can empower individuals to take proactive steps towards optimal cardiovascular wellness.

View
14 Nov

Navigating World Diabetes Day in India: A Closer Look at the Battle Against Diabetes

According to the World Health Organization (WHO), a significant 77 million individuals aged 18 and above in India are struggling with type 2 diabetes. Additionally, an extra 25 million hover on the brink of prediabetes.

View
04 Jul

The Power of Vitamin D: Can it Help in Preventing Cardiovascular Disease

Vitamin D deficiency is a significant concern in India, and it is important to recognize its potential impact on cardiovascular health. By understanding the importance of Vitamin D and adopting strategies to maintain optimal levels, we can potentially reduce the risk of heart attacks among the Indian population.

View
06 Mar

Sushmita Sen reveals about suffering from a severe heart attack recently and Addison's disease in 2014

Sushmita Sen says having an active lifestyle helped me survive the severe heart attack with 95% blockage in main artery. She also revealed her diagnosis of Addison's disease.

View
12 Jan

Risks and Benefits of Percutaneous Coronary Interventions

Percutaneous coronary intervention is one of the safest treatments for treating coronary artery disease, which can be fatal. Let's know more about it.

View

-Advertisements-




Trending Now

Strength Doesn’t Retire: The Science Behind Ageless PowerApril 04, 2025
Beyond the Baby Bump: Can Delayed Pregnancy Increase Autism Risk in ChildrenApril 04, 2025
University of Manchester invites applications for MA Social AnthropologyApril 03, 2025
Ahead of World Health Day, Sova Health Launches Advanced Microbiome Tests & Evidence-Based Precision Supplements April 03, 2025
Half of women cannot make decisions about their reproductive health and bodily autonomyApril 03, 2025
UGRO CAPITAL LIMITED PUBLIC ISSUE OF SECURED, RATED, LISTED, REDEEMABLE, NON-CONVERTIBLE DEBENTURES (SECURED NCDS) OPENS TODAY EFFECTIVE ANNUALIZED YIELD UP TO 11.01% PER ANNUM* April 03, 2025
SF Airlines Entrusts Çelebi India with Freighter Handling at Kempegowda International Airport, BengaluruApril 03, 2025
Is This the Future of Physiotherapy? Inside Stance Health’s $1M ExpansionApril 03, 2025
The Daily Shower Debate: Are You Washing Away Your Skin’s Health?April 03, 2025
The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025